Evidence map›Paper›PMID 18644797›Full record

ArticleNephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association2008

The improvement of renal survival with steroid pulse therapy in IgA nephropathy.

Ritsuko Katafuchi, Toshiharu Ninomiya, Tohru Mizumasa, Kiyoshi Ikeda, Harumitsu Kumagai, Masaharu Nagata, Hideki Hirakata

Erratum issuedOpen access · hybridAbstract read
In one paragraph

Article in Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 16 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 2 pooled it
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 46 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Observational
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

  • Erratum issued
5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Ritsuko KatafuchiKidney Unit, Fukuoka Red Cross Hospital, Fukuoka, Japan. katafuchir@fukuokae2.hosp.go.jp
Toshiharu Ninomiya
Tohru Mizumasa
Kiyoshi Ikeda
Harumitsu Kumagai
Masaharu Nagata
Hideki Hirakata
Red Cross Hospital · GRKyushu University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe benefits of steroid therapy in immunoglobulin A nephropathy (IgAN) have not been established.

methodsThe effect of steroids on kidney survival was retrospectively investigated in 702 patients with IgAN by multivariate analyses.

resultsThere were 295 men and 407 women. The median follow-up period was 62 months. One hundred and ninety-four patients were treated with oral steroids (oral steroid group). Thirty-four patients were treated with methylprednisolone (mPSL) pulse therapy (pulse steroid group) followed by oral prednisolone (PSL). In 474 patients, no steroid was used (no steroid group). The urinary protein-creatinine ratio and histological grade were significantly different among treatment groups and were highest in the pulse steroid group followed by the oral steroid group and lowest in the no steroid patients. Serum creatinine was significantly higher in the pulse steroid group than in other two groups. Eighty-five patients developed end-stage renal failure (ESRF) requiring dialysis. [corrected] In multivariate analysis, steroid pulse therapy significantly decreased the risk of ESRF while oral steroid treatment did not improve renal survival in this cohort.

conclusionWe found that pulse steroid therapy improved kidney survivals in IgAN. Since the clinical findings and histological grade were the most severe in patients treated with mPSL pulse therapy, such therapy may prevent progression of IgAN.

Indexed as

Adrenal Cortex HormonesAdultFemaleGlomerulonephritis, IGAHumansKidney Failure, ChronicMaleMethylprednisoloneMiddle AgedMultivariate AnalysisPrednisoloneProportional Hazards ModelsRetrospective StudiesRisk FactorsYoung AdultAdrenal Cortex HormonesMethylprednisolonePrednisolone

Identifiers

PMID18644797
PMCPMC2639065
OpenAlexW2166573358

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.